drugset / Trial / NCT06708611

A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs

NCT06708611

Phase 4 Withdrawn Sarfez Pharmaceuticals, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a randomized double-blind crossover study of the patients with stable heart failure, who are taking a loop diuretic. During the study period, the participants' loop diuretics will be replaced by the equivalent dose of immediate release/extended release torsemide for one week. After a one week period, they will report to the site and will receive a single dose of either immediate release or extended release Torsemide. The sodium excretion will be measured for six hours after dosing and for an additional six hours after a high salt lunch.

Timeline

Start
2025-01-15
Primary completion
2025-03-25
Completion
2025-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Torsemide Other / unclassified 20 mg Oral
Subject Torsemide Other / unclassified 24 mg Oral

Indications